Renal · Electrolyte Disorders
The facts most likely to be tested
Chronic Kidney Disease (CKD) is the most common cause of hyperphosphatemia due to decreased glomerular filtration rate (GFR) and impaired phosphate excretion.
Hyperphosphatemia leads to hypocalcemia because excess phosphate binds to calcium, causing metastatic calcification in soft tissues and blood vessels.
Secondary hyperparathyroidism occurs as a compensatory response to hyperphosphatemia, leading to increased parathyroid hormone (PTH) secretion to promote phosphate excretion.
Tumor Lysis Syndrome (TLS) is a high-yield cause of acute hyperphosphatemia, often presenting with hyperkalemia, hyperuricemia, and acute kidney injury following chemotherapy.
Clinical manifestations of hyperphosphatemia are primarily driven by associated hypocalcemia, presenting as tetany, Chvostek sign, Trousseau sign, and perioral paresthesias.
Phosphate binders such as sevelamer, calcium acetate, or lanthanum carbonate are the first-line pharmacological treatments to reduce dietary phosphate absorption in patients with CKD.
Renal osteodystrophy is a long-term complication of chronic hyperphosphatemia and secondary hyperparathyroidism, manifesting as bone pain and increased risk of pathologic fractures.
Vignette unlocked
A 58-year-old male with a history of end-stage renal disease (ESRD) on hemodialysis presents to the clinic complaining of muscle cramps and tingling around his mouth. Physical examination reveals a positive Chvostek sign and dry, pruritic skin. Laboratory studies show a serum phosphate of 7.2 mg/dL and a serum calcium of 7.4 mg/dL. The patient is currently non-adherent to his prescribed dietary restrictions and medication regimen.
Which of the following is the most appropriate next step in the management of this patient's hyperphosphatemia?
Initiation of a phosphate binder such as sevelamer
The patient exhibits signs of hypocalcemia secondary to hyperphosphatemia caused by ESRD; phosphate binders are required to reduce intestinal absorption of dietary phosphate.
Full handout
High yield triage
Etiology / Epidemiology
Most common in chronic kidney disease (CKD) due to decreased renal excretion. Also seen in tumor lysis syndrome and excessive intake.
Clinical Manifestations
Symptoms driven by hypocalcemia; look for Chvostek sign, Trousseau sign, and tetany. Metastatic calcification is a late finding.
Diagnosis
Serum phosphate > 4.5 mg/dL. Serum chemistry panel is the diagnostic standard.
Treatment
Restrict dietary intake and use phosphate binders (e.g., calcium carbonate). Avoid aluminum-based binders in long-term use.
Prognosis
Risk of metastatic calcification and secondary hyperparathyroidism. Monitor calcium-phosphate product to prevent vascular calcification.
Full handout
Epidemiology & Etiology
Primary etiology is decreased renal excretion in patients with advanced CKD. Acute cases often result from tumor lysis syndrome or rhabdomyolysis causing massive intracellular release. Excessive exogenous intake via phosphate-containing laxatives is a rare but preventable cause.
Pertinent Anatomy
The kidneys are the primary site of phosphate excretion, regulated by parathyroid hormone (PTH). The bones act as a reservoir, while the GI tract is the site of absorption.
Pathophysiology
Elevated serum phosphate leads to the precipitation of calcium-phosphate crystals in soft tissues, causing metastatic calcification. High phosphate levels suppress 1-alpha-hydroxylase, decreasing active vitamin D production. This results in hypocalcemia, which triggers secondary hyperparathyroidism to restore calcium homeostasis.
Clinical Manifestations
Patients often present with symptoms of secondary hypocalcemia, including perioral paresthesias, Chvostek sign, and Trousseau sign. Severe cases manifest as tetany, seizures, or cardiac arrhythmias. Red flags include metastatic calcification in vessels, joints, and skin, which can lead to ischemic necrosis.
Diagnosis
Diagnosis is confirmed via serum chemistry panel showing phosphate > 4.5 mg/dL. Evaluation must include serum calcium and PTH levels to assess for secondary hyperparathyroidism. The calcium-phosphate product (Ca x PO4) should be calculated; values > 55 mg²/dL² indicate high risk for tissue calcification.
Treatment
Initial management focuses on dietary restriction of phosphate. Phosphate binders (e.g., calcium carbonate or calcium acetate) are the first-line agents taken with meals. Avoid aluminum-based binders due to risks of neurotoxicity and bone disease. In acute, severe cases, IV saline hydration and forced diuresis are required.
Prognosis
Chronic elevation leads to renal osteodystrophy and increased cardiovascular mortality. Strict monitoring of the calcium-phosphate product is required to prevent systemic vascular calcification.
Differential Diagnosis
Hypoparathyroidism: low PTH levels
Tumor Lysis Syndrome: elevated uric acid and potassium
Rhabdomyolysis: elevated CK and myoglobinuria
Vitamin D Toxicity: elevated 25-hydroxyvitamin D
Milk-Alkali Syndrome: hypercalcemia with metabolic alkalosis